Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, announced that Greg Bleck, Ph.D., Global Head of R&D, Catalent Biologics will present at the upcoming annual PEGS Europe conference, which will be held at the Lisboa Congress Center, Lisbon, Portugal.
Dr. Bleck will speak as part of the conference’s “Cell Line and Systems Engineering” track. His presentation, entitled “GPEx® Boost Technology: A Novel Approach for High-Expressing CHO Cell Line Engineering,” will demonstrate how Catalent’s new cell line technology can allow greater productivity, streamlined development and the reduction of cost of goods. The presentation will include case studies to make comparisons between the traditional GPEx cell line development technology, used to create high-yielding mammalian cell lines, and GPEx Boost technologies.
GPEx Boost cell line development technology was launched in November 2019 and combines Catalent’s proprietary GPEx technology and a glutamine synthase knock-out Chinese hamster ovary (CHO) cell line.
In his role at Catalent, Dr. Bleck has overall responsibility for the development and acquisition of new products and technologies. He was an original employee of Gala Biotech (acquired by Catalent), where he used his knowledge of gene expression and transgenic systems to develop and optimize retroviral vector expression systems and the proprietary GPEx process. Prior to joining Gala, he performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and expression. Dr. Bleck holds a bachelor’s degree and a doctorate in endocrinology-reproductive physiology, both from the University of Wisconsin-Madison. He has published over 60 research papers, co-authored three book chapters, and is the sole inventor or co-inventor on multiple patents.
For further information on this event, visit https://www.catalent.com/index.php/news-events/events/PEGS-Europe.
To arrange a meeting with Dr. Bleck or any of the other Catalent experts attending the event, contact Richard Kerns at NEPR – firstname.lastname@example.org
ABOUT CATALENT BIOLOGICS
For more than two decades, Catalent Biologics has built capabilities and experience in development, manufacturing, and analytical services for new biological entities, gene therapies, biosimilars, and antibody-drug conjugates. Catalent Biologics has worked with 600+ mAbs and 80+ proteins, and 12 biopharmaceutical drugs produced using GPEx® technology have been approved and marketed, with more than 120+ ongoing clinical trials utilizing therapeutic candidates developed using the GPEx platform. A further 25 commercially-approved products have employed Catalent Biologics’ capabilities through to aseptic fill/finish. Catalent’s latest addition, Paragon Gene Therapy’s AAV development through commercial-scale manufacturing facilities in Baltimore, Maryland, has produced over 100 clinical GMP batches across 40 programs. Using advanced protein improvement technology and tailored solutions from DNA through to clinical and commercial supply, Catalent Biologics brings better biologic treatments to patients, faster. For more information, visit biologics.catalent.com
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including approximately 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com